Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Prostate Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., Cheng, H. H., D'Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Guzzo, T., Ippolito, J. E., Karnes, R. J., Kuettel, M. R., Lang, J. M., Lotan, T., McKay, R. R., Morgan, T., Pow-Sang, J. M., Reiter, R., Roach, M., Robin, T., Rosenfeld, S., Shabsigh, A., Spratt, D., Szmulewitz, R., Teply, B. A., Tward, J., Valicenti, R., Wong, J. K., Snedeker, J., Freedman-Cass, D. A. 2024; 22 (3): 140-150

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.

View details for DOI 10.6004/jnccn.2024.0019

View details for PubMedID 38626801